June 12, 2024 07:23 AM EDTUpdated 12:41 PM

China biotech ban does not make the cut as add-on to defense spending bill

Zachary Brennan

Senior Editor

A bipartisan bill that would essentially ban US biotech companies from using certain Chinese suppliers failed to muster the support needed to hitch a ride …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

China biotech ban does not make the cut as add-on to defense spending bill

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Exclusive: J&J folds cardiovascular and metabolic drug unit

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Chi­na biotech ban does not make the cut as add-on to de­fense spend­ing bill

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

China biotech ban does not make the cut as add-on to defense spending bill